|
Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions
for International Phase III Study in Parkinson’s Disease
Fort Lauderdale, FL, August 20, 2009 -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM.OB ), one of the fastest growing companies in the EDC marketplace,
today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA,
has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson’s Disease.
"While managing a global multi site clinical trial there can be significant challenges in getting trial data when
you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax.
"The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process.
After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach
and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has
enabled us to meet our very tight corporate timelines for this important study."
"We look forward to working with Impax to assist them in the fight to cure Parkinson’s disease," remarked
Stephen Johnson, COO of OmniComm Systems. "We are honored that after an extensive evaluation,
OmniComm’s electronic data capture solution, TrialMasterTM, was chosen to capture and process their clinical trial data.
TrialMasterTM will enable them to continue to make informed and strategic decisions that will be vital to their
success as a company."
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise
and drug delivery technology to the development of controlled-release and specialty generics in addition to the
development of branded products. Impax markets its generic products through its Global Pharmaceuticals division
and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically
appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and
Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical,
biotechnology, research and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver
products and services that ensure ease of use, faster study build, ease of integration and better performance.
OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale
institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has
U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in
New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the
sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand.
As a result, actual results may differ materially from any financial outlooks stated herein. Further information on
potential factors that could affect the Company's financial results can be found in the Company's Reports on Form
10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
